Skip to content

US · SINT · MEDICAL - DEVICES

Sintx Technologies, Inc. (SINT) intrinsic value and stock valuation

$1.10as of 2026-11-21 · Mkt cap 6.84M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Sintx Technologies, Inc. DCF and intrinsic value

InvestorsCraft values SINT with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from SINT’s statements →

Sintx Technologies, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Salt Lake City, UT 84119 sintx.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$1.02M+11.6% 5y CAGRd
20112025
Net income
-$-17.08M
20112025
Free cash flow
-$-8.76M
20112025
Total equity
$2.93M-35.3% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$1.02M$1.25M$2.63M$600K$610K
Operating income-$-10.72M-$-14.05M-$-13.36M-$-11.34M-$-10.62M
Net income-$-17.08M-$-11.02M-$-8.26M-$-12.04M-$-9.31M
EPSd-$-6.17M-$-14.89M-$-19.21M-$-37.63M-$-37.24M
Operating cash flow-$-8.57M-$-8.64M-$-14.12M-$-10.26M-$-10.13M
Capital expenditure-$-180K-$-690K-$-530K-$-1.41M-$-3.74M
Free cash flow-$-8.76M-$-9.33M-$-14.64M-$-11.67M-$-13.87M
Total assets$9.51M$9.41M$15.4M$15.8M$21.8M
Total debt$3.25M$4.03M$4.76M$3.62M$2.91M
Net debt-$-890K$430K$1.42M-$-2.62M-$-11.37M
Total equity$2.93M$3.89M$8.77M$5.7M$17.2M
Cash and short-term investments$4.14M$3.6M$3.34M$6.25M$14.3M
Income statement
20252024202320222021
Revenue$1.02M$1.25M$2.63M$600K$610K
Cost of revenue$1.22M$810K$780K$270K$450K
Gross profit-$-200K$430K$1.84M$340K$160K
Research and development expenses$4.59M$5.2M$8.71M$6.45M$5.89M
Selling, general and administrative expenses$6.44M$4.61M$5.36M$5.33M$4.89M
Other expenses-$-510K$4.67M$1.13M-$-100K$0.00
Operating expenses$10.5M$14.5M$15.2M$11.7M$10.8M
Cost and expenses$11.7M$15.3M$16M$11.9M$11.2M
Interest income$170K$110K$140K$20K$100K
Interest expense$50K$30K$0.00$20K$30K
Depreciation and amortization$660K$1.38M$1.66M$960K$650K
Ebitda-$-9.65M-$-9.61M-$-6.6M-$-11.06M-$-8.63M
Operating income-$-10.72M-$-14.05M-$-13.36M-$-11.34M-$-10.62M
Total other income/expenses, net$360K$3.02M$5.1M-$-700K$1.31M
Income before tax-$-10.36M-$-11.02M-$-8.26M-$-12.04M-$-9.31M
Income tax expense$6.72M$0.00$0.00$0.00$0.00
Net income-$-17.08M-$-11.02M-$-8.26M-$-12.04M-$-9.31M
Weighted average shares outstanding$2.77M$740K$380K$300K$210K
Weighted average diluted shares outstanding$2.77M$740K$430K$320K$250K
Balance sheet
20252024202320222021
Cash and short-term investments$4.14M$3.6M$3.34M$6.25M$14.3M
Net receivables$180K$200K$690K$330K$100K
Inventory$820K$500K$890K$280K$300K
Total current assets$5.65M$4.77M$5.53M$7.21M$15M
Property, plant and equipment, net$2.93M$4.08M$8.92M$8M$6.41M
Goodwill and intangible assets$440K$20K$20K$30K$30K
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$3.86M$4.64M$9.83M$8.56M$6.81M
Total assets$9.51M$9.41M$15.4M$15.8M$21.8M
Accounts payable$380K$300K$640K$430K$240K
Short-term debt$410K$490K$1.07M$1.64M$1.01M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$3.73M$1.98M$2.91M$8.08M$2.75M
Long-term debt$2.84M$3.54M$3.69M$1.99M$1.9M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$2.84M$3.54M$3.69M$1.99M$1.9M
Capital lease obligations$3.24M$3.99M$4.2M$2.36M$2.4M
Total liabilities$6.58M$5.52M$6.59M$10.1M$4.64M
Common stock$40K$10K$50K$10K$0.00
Retained earnings-$-292.1M-$-281.74M-$-270.71M-$-262.45M-$-250.42M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$2.93M$3.89M$8.77M$5.7M$17.2M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$3.25M$4.03M$4.76M$3.62M$2.91M
Net debt-$-890K$430K$1.42M-$-2.62M-$-11.37M
Cash flow statement
20252024202320222021
Net income-$-10.36M-$-11.02M-$-8.26M-$-12.04M-$-9.31M
Depreciation and amortization$640K$1.38M$1.66M$960K$650K
Stock-based compensation$1.39M$0.00$0.00$370K$0.00
Change in working capital-$-720K-$-230K-$-2.24M-$-60K-$-480K
Accounts receivable-$-70K$490K-$-420K-$-30K-$-60K
Inventory-$-90K$70K-$-480K-$-140K-$-110K
Accounts payable-$-200K-$-760K-$-10K$0.00$260K
Net cash provided by operating activities-$-8.57M-$-8.64M-$-14.12M-$-10.26M-$-10.13M
Investments in property, plant and equipment-$-180K-$-690K-$-530K-$-1.41M-$-3.74M
Acquisitions, net$1.1M$20K$30K$300K$140K
Net cash used for investing activities$910K-$-190K-$-500K-$-1.1M-$-1.66M
Common stock issued$8.54M$9.44M$5.18M$0.00$200K
Common stock repurchased-$-130K$0.00-$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$8.2M$9.09M$11.7M$3.34M$700K
Net change in cash$540K$260K-$-2.9M-$-8.03M-$-11.08M
Cash at end of period$4.14M$3.6M$3.34M$6.25M$14.3M
Operating cash flow-$-8.57M-$-8.64M-$-14.12M-$-10.26M-$-10.13M
Capital expenditure-$-180K-$-690K-$-530K-$-1.41M-$-3.74M
Free cash flow-$-8.76M-$-9.33M-$-14.64M-$-11.67M-$-13.87M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Sintx Technologies, Inc.

        Sintx Technologies, Inc. is an advanced materials enterprise dedicated to researching, developing, and commercializing medical devices crafted from silicon nitride. These innovative products serve biomedical, industrial, and antipathogenic uses, primarily marketed across the United States. Its diverse portfolio includes solid and porous silicon nitride, silicon nitride powder, and specialized coating products, along with advanced silicon nitride composite materials and polyetherketoneketone. Established in 1996, this company, once known as Amedica Corporation, has its corporate headquarters situated in Salt Lake City, Utah.

        CEO
        Eric K. Olson
        Employees
        32
        Beta
        0.63

        Explore

        Frequently asked questions

        What is the intrinsic value of Sintx Technologies, Inc. (SINT)?

        Sintx Technologies, Inc. (SINT) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is SINT undervalued?

        SINT trades at a price of $1.10 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.